Venn Life Sciences Holdings PLC Result of General Meeting (6658D)
27 June 2019 - 8:02PM
UK Regulatory
TIDMVENN
RNS Number : 6658D
Venn Life Sciences Holdings PLC
27 June 2019
27 June 2019
Venn Life Sciences Holdings Plc
("Venn Life Sciences" or the "Company")
Result of General Meeting
Venn Life Sciences is pleased to announce that at the Company's
General Meeting held earlier today in relation to the Company's
proposed acquisition of Open Orphan and connected Placing, all of
the Resolutions put to the meeting were duly passed.
The Board is pleased to note that each Resolution was
unanimously passed by Shareholders. The Board is excited by the
growth potential of the Enlarged Group following completion of the
Proposals and looks forward to updating Shareholders on the
Company's progress going forward.
Director Appointment
As announced on 10 May 2019 and described in the Company's
admission document dated 11 June 2019 ("Admission Document"), Dr
Maurice Treacy will be appointed as an Executive Director of the
Company with effect from Admission.
Admission and Change of Name
Application has been made for the admission of the Enlarged
Share Capital to trading on AIM and Euronext Growth, which is
expected to become effective and dealings commence at 8.00 a.m. on
28 June 2019.
The change of name of the Company to Open Orphan plc is expected
to take effect later today and the change of TIDM to "ORPH" is
expected to take effect from Admission.
Total voting rights
Following Admission, the total number of ordinary shares of 0.1
pence each ("Ordinary Shares") in issue with voting rights will be
253,493,259 Ordinary Shares and Shareholders may use this figure as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or change to
their interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.
Unless otherwise defined, capitalised terms used in this
announcement are as defined in the Admission Document.
Enquiries:
Venn Life Sciences Holdings Plc Tel: +353 1 644 0007
Cathal Friel, Chief Executive Officer
Arden Partners (Nominated Adviser and Joint Broker) Tel: +44
(0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer
Davy (Euronext Growth Advisor and Joint Broker) Tel: +353 (0)1
679 6363
Anthony Farrell (Corporate Finance)
Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen
About Venn Life Sciences
Venn Life Sciences is an Integrated Drug Development Partner
offering a combination of drug development expertise and clinical
trial design and management to pharmaceutical, biotechnology and
medical device organisations. Venn Life Sciences has dedicated
operations in France, Germany, the Netherlands, the UK and Ireland
with partners across Europe and the US.
Further information in relation to Venn Life Sciences
www.Vennlifesciences.com
Venn Life Sciences: getintouch@Vennlife.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ROMSEFFSWFUSESM
(END) Dow Jones Newswires
June 27, 2019 06:02 ET (10:02 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Jul 2023 to Jul 2024